SCHEMBL1733665

SCHEMBL1733665

CCN(CC)c1nc(C(N)=O)cc(-c2cccc(C)c2C)n1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.64
NUDT1 P36639 3/20 0.40
AVPR2 P30518 2/20 0.39
OXTR P30559 2/20 0.39
CDC7 O00311 1/20 0.38
PLK4 O00444 1/20 0.38
MAPK13 O15264 1/20 0.38
PDPK1 O15530 1/20 0.38
DAPK3 O43293 1/20 0.38
DYRK3 O43781 1/20 0.38
JAK2 O60674 1/20 0.38
ROCK2 O75116 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38
PRKCG P05129 1/20 0.38
CDK1 P06493 1/20 0.38
PIM1 P11309 1/20 0.38
FGFR1 P11362 1/20 0.38
PRKACA P17612 1/20 0.38
CDK2 P24941 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1733748 0.90 KDM4E (0.70) KDM4EOXTRJAK2MAP4K2ADORA2A
SCHEMBL1734561 0.82 KDM4E (0.62) KDM4ENUDT1PIM1PIM3GRM2
SCHEMBL1733617 0.81 KDM4E (0.69) KDM4EADORA2AADORA1GRM2
SCHEMBL1734477 0.81 KDM4E (0.65) KDM4EADORA2AADORA1MEN1KMT2A
SCHEMBL1734511 0.80 KDM4E (0.66) KDM4EADORA2AADORA1
SCHEMBL1733513 0.79 KDM4E (0.77) KDM4EMAPK1CSNK1DTLR8ADORA2A
SCHEMBL1733607 0.78 KDM4E (1.00) KDM4EMAPK1ADORA2AADORA1MEN1
SCHEMBL1734327 0.78 KDM4E (0.70) KDM4EMAPK1GRM2MEN1KMT2A
SCHEMBL1734432 0.78 KDM4E (0.67) KDM4EJAK2PIM1PIM3GRM2
SCHEMBL1735810 0.77 KDM4E (0.78) KDM4EMAPK1ADORA2AADORA1GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US claimed
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP claimed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO claimed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US claimed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 KDM4E 3910/4885NUDT1 113/4885AVPR2 4263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.